Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Aug;34(5):320-330.
doi: 10.1080/08880018.2017.1373315. Epub 2017 Oct 17.

Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States

Diarmuid Coughlan  1 , Matthew Gianferante  2 , Charles F Lynch  3 , Jennifer L Stevens  4 , Linda C Harlan  1
Affiliations
Clinical Trial

Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States

Diarmuid Coughlan et al. Pediatr Hematol Oncol. 2017 Aug.

Abstract

Background: Childhood neuroblastoma describes a heterogeneous group of extracranial solid tumors, that are treated per risk profile. We sought to describe treatment patterns and survival using population-based data from throughout the United States.

Materials and methods: Using the National Cancer Institute (NCI)'s Patterns of Care data, we analyzed treatment provided to newly diagnosed, histologically confirmed neuroblastoma patients in 2010 and 2011, registered to one of 14 Surveillance, Epidemiology, and End Results (SEER) cancer registries. Data were re-abstracted from hospital records and treating physicians contacted for verification. Application of the Children's Oncology Group (COG)'s 3-level (low, intermediate and high) neuroblastoma risk classification system for therapeutic decision-making provided insight to community-based treatment patterns. Kaplan-Meier survival analyses, based on 5-years of follow-up, were also performed.

Results: 76% of the 250 patients were enrolled on an open/active clinical trial. All low-risk patients received surgery. Most intermediate-risk patients (81%) received a chemotherapy regimen that included carboplatin, etoposide, cyclophosphamide and doxorubicin. High-risk patients received extensive, multimodal treatment consisting of chemotherapy, surgery, myeloablative chemotherapy with stem cell rescue (transplant), radiation, immunotherapy (dinutuximab), and isotretinoin therapy. 21% patients had died at the end of the maximum 60-month follow-up period. The 5-year estimated survival rates were lower for patients diagnosed with stage 4 disease, unfavorable DNA ploidy, MYCN gene amplification or classified as high-risk.

Conclusion: Most neuroblastoma patients are registered on a risk-based open/active clinical trial. Variation in modality, systemic agents and sequence of treatment reflects the heterogeneity of therapy received by these patients.

Keywords: Immunotherapy; neuroblastoma; survival; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors report no conflicts of interest.

The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This article was produced by employees of the US government as part of their official duties and, as such, is in the public domain in the United States of America. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Figures

Figure 1:
Figure 1:
Percentage completion and termination of top 10 systemic agents in Neuroblastoma diagnosed in 2010–11 (weighed)
Figure 2:
Figure 2:
Kaplan-Meier all-cause survival curve for childhood neuroblastoma patients by A) risk profile B) INSS staging C) DNA ploidy D) MYCN gene amplification
See this image and copyright information in PMC

References

    1. Jiang M, Stanke J, Lahti JM. The Connections Between Neural Crest Development and Neuroblastoma. Curr Top Dev Biol 2011;94:77–127. - PMC - PubMed
    1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–16. - PubMed
    1. St. Jude’s Children Research Hospital Website. Neuroblastoma. https://www.stjude.org/disease/neuroblastoma.html (Accessed June 14, 2017).
    1. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012;256:573–80. - PMC - PubMed
    1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008; 55:97–120. - PubMed